Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The HER-2/ neu oncogene is a member of the erb B-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/ neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of the HER-2/ neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/ neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CNVs are involved in a large number of complex human diseases such as Down’s syndrome (trisomy 21) and many cancers, for example HER2 gene amplification in breast cancer (BC) (1–5).”
From Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation (2012) · cites this paper as [5]
In the citing paper
“In a seminal study, Slamon et al. found that HER2 is amplified in about 20% of breast cancers (Slamon et al., 1987).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Slamon et al., 1987
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene
Greenberg, M. E., & Ziff, E. B. (1984) · Nature · doi:10.1038/311433a0 · Cited by 3,064
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Self-citationClose similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., & Waterfield, M. D. (1984) · Nature · doi:10.1038/307521a0 · Cited by 2,516
Self-citationAmplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas
Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Self-citation
Research works printed but not linked: 1
- Maniatis, T., Molecular Cloning: A Laboratory Manual: 282 (1982).
Cited by
Items 701–800 of 1,056
The role of EGF-related peptides in tumor growth
Normanno, N. (2001) · Frontiers in Bioscience · doi:10.2741/a635 · Cited by 216
“However, overexpression without amplification has also been described (104).”
BackgroundTrastuzumab-modified nanoparticles: Optimisation of preparation and uptake in cancer cells
Steinhauser, I., Spänkuch, B., Strebhardt, K., & Langer, K. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.05.016 · Cited by 216
Dybdal, N., Leiberman, G., Anderson, S., McCune, B., Bajamonde, A., Cohen, R. L., Mass, R. D., Sanders, C., & Press, M. F. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-6275-8 · Cited by 216
“The incidence of HER2 gene amplification in these patients was estimated to be 25%, consistent with previous reports of HER2 amplification rates in breast cancer tissue specimens [4, 6, 7].”
ResultProteomics Analysis of Conditioned Media from Three Breast Cancer Cell Lines
Kulasingam, V., & Diamandis, E. P. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m600465-mcp200 · Cited by 216
“associated with a high risk of relapse and death (33) and is the”
BackgroundFeng, W. W., Wilkins, O., Bang, S., Ung, M., Li, J., An, J., del Genio, C., Canfield, K., DiRenzo, J., Wells, W., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.008 · Cited by 216
“In particular, the FASN pathway is highly active in cancers overexpressing the receptor tyrosine kinase HER2 (human epidermal growth factor receptor 2, ERBB2), which promotes both FASN gene transcription and phospho-activation of FASN protein (Slamon et al., 1987; Kumar-Sinha et al., 2003; Jin et al., 2010).”
BackgroundPhosphoproteomic analysis of Her2/neu signaling and inhibition
Bose, R., Molina, H., Patterson, A. S., Bitok, J. K., Periaswamy, B., Bader, J. S., Pandey, A., & Cole, P. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603948103 · Cited by 215
McAlpine, J. N., Wiegand, K. C., Vang, R., Ronnett, B. M., Adamiak, A., Köbel, M., Kalloger, S. E., Swenerton, K. D., Huntsman, D. G., Gilks, C. B., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-433 · Cited by 215
“Amplification and overexpression of HER2 is seen in approximately 15% of breast carcinomas and is associated with a poor prognosis [10-14].”
BackgroundBartlett, J. M. S., Bayani, J., Marshall, A., Dunn, J. A., Campbell, A., Cunningham, C., Sobol, M. S., Hall, P. S., Poole, C. J., Cameron, D. A., et al. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw050 · Cited by 215
van Maaren, M. C., de Munck, L., Strobbe, L. J. A., Sonke, G. S., Westenend, P. J., Smidt, M. L., Poortmans, P. M., & Siesling, S. (2018) · International Journal of Cancer · doi:10.1002/ijc.31914 · Cited by 215
“shown to be an important prognostic and predictive factor in breast cancer.(7,8) The prognostic and predictive value of ER, PR and HER2 status increases when the three are combined.”
BackgroundSrinivasan, R., Poulsom, R., Hurst, H. C., & Gullick, W. J. (1998) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199807)185:3<236::aid-path118>3.0.co;2-7 · Cited by 215
Gm, B., Hayes, F. A., Green, A. A., Casper, J., Wasson, J., Wallach, S., & Seeger, R. C. (1987) · PubMed · Cited by 215
Minimal Model: Perspective from 2005
Bergman, R. N. (2005) · Hormone Research in Paediatrics · doi:10.1159/000089312 · Cited by 214
Prognostic value of ERBB family mRNA expression in breast carcinomas
Bièche, I., Onody, P., Tozlu, S., Driouch, K., Vidaud, M., & Lidereau, R. (2003) · International Journal of Cancer · doi:10.1002/ijc.11273 · Cited by 214
FDA Drug Approval Summary: Panitumumab (Vectibix™)
Giusti, R. M., Shastri, K. A., Cohen, M. H., Keegan, P., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-577 · Cited by 214
Perez, E. A., Roche, P. C., Jenkins, R. B., Reynolds, C. A., Halling, K. C., Ingle, J. N., & Wold, L. E. (2002) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)62329-x · Cited by 214
MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer
Andorfer, C. A., Necela, B. M., Thompson, E. A., & Perez, E. A. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.006 · Cited by 214
Lee, S. W. (1996) · Nature Medicine · doi:10.1038/nm0796-776 · Cited by 214
HER-2-targeted therapy: lessons learned and future directions.
Nahta, R., & Esteva, F. J. (2003) · PubMed · Cited by 214
Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors.
Siegel, P. M., Dankort, D. L., Hardy, W. R., & Muller, W. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.11.7068 · Cited by 213
“Amplification and consequent overexpression of neulc-erbB-2 have also been observed in a significant proportion of human breast and ovarian cancers (14, 24, 27).”
BackgroundBalsamo, J., Leung, T., Ernst, H., Zanin, M. K., Hoffman, S., & Lilien, J. (1996) · The Journal of cell biology · doi:10.1083/jcb.134.3.801 · Cited by 213
“Consistent with this possibility , amplification or overexpression of c-erbB-2 has been correlated with highly malignant tumors and poor prognosis (Slamon et al., 1987).”
Aberrant function of the Ras signal transduction pathway in human breast cancer
Clark, G. J., & Der, C. J. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00694753 · Cited by 213
“Additionally, the closely related HER-2/neu receptor tyrosine kinase is frequently amplified in breast cancers and is perhaps the most consistent oncogene marker for breast cancer [35, 36 ].”
BackgroundSelf-citationHighly Sensitive Detection of Protein Biomarkers with Organic Electrochemical Transistors
Fu, Y., Wang, N., Yang, A., Law, H. K., Li, L., & Yan, F. (2017) · Advanced Materials · doi:10.1002/adma.201703787 · Cited by 213
The role of HER2 in angiogenesis
KUMAR, R. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90279-9 · Cited by 212
Kapitanovic, S., Radosevic, S., Kapitanovic, M., Andelinovic, S., Ferencic, Z., Tavassoli, M., Primorac, D., Sonicki, Z., Spaventi, S., Pavelic, K., et al. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70120-3 · Cited by 212
Braun, S., Schlimok, G., Heumos, I., Schaller, G., Riethdorf, L., Riethmüller, G., & Pantel, K. (2001) · PubMed · Cited by 212
Platinum-based chemotherapy in metastatic breast cancer: current status
Decatris, M. P., Sundar, S., & O’Byrne, K. J. (2004) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00139-7 · Cited by 211
Day, J. D., Digiuseppe, J. A., Yeo, C., Lai-Goldman, M., Anderson, S. M., Goodman, S. N., Kern, S. E., & Hruban, R. H. (1996) · Human Pathology · doi:10.1016/s0046-8177(96)90364-0 · Cited by 211
Wainberg, Z. A., Anghel, A., Desai, A. J., Ayala, R., Luo, T., Safran, B., Fejzo, M. S., Hecht, J. R., Slamon, D. J., & Finn, R. S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1112 · Cited by 211
“org sion and/or amplification has been detected in 20% to 27% of invasive breast cancers and correlates with poorer clinical outcomes (3, 4).”
BackgroundSelf-citationGuerin, M., Gabillot, M., Mathieu, M., Travagli, J., Spielmann, M., Andrieu, N., & RIOU, G. F. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910430205 · Cited by 211
Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity.
Yang, D., Hendifar, A. E., Lenz, C., Togawa, K., Lenz, F., Lurje, G., Pohl, A., Winder, T. L., Ning, Y., Groshen, S. G., et al. (2011) · PubMed · doi:10.3978/j.issn.2078-6891.2010.025 · Cited by 210
“Over-expression of the H2N protein has been identified in from 10 to 34% of breast cancers and is associated with a poor prognosis (43).”
BackgroundCauses of death after breast cancer diagnosis: A US population‐based analysis
Afifi, A. M., Saad, A. M., Al‐Husseini, M. J., Elmehrath, A. O., Northfelt, D. W., & Sonbol, M. B. (2020) · Cancer · doi:10.1002/cncr.32648 · Cited by 210
“Cardiotoxicity is a recognized adverse event of the anthracyclines and HER2-directed agents.(17-19) This toxicity is dose-dependent with anthracyclines and results in the development of heart failure and cardiomyopathy.”
BackgroundAXL Is a Potential Target for Therapeutic Intervention in Breast Cancer Progression
Zhang, Y.-X., Knyazev, P. G., Cheburkin, Y. V., Sharma, K., Knyazev, Y. P., Őrfi, L., Szabadkai, I., Daub, H., Kéri, G., & Ullrich, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2661 · Cited by 210
Self-citationPI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1
Ebi, H., Costa, C., Faber, A. C., Nishtala, M., Kotani, H., Juric, D., Della Pelle, P., Song, Y., Yano, S., Mino-Kenudson, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314124110 · Cited by 210
“Proc Natl Acad Sci USA 109(8):2724–2729.”
BackgroundInfluential10 Curcumin — Biological and Medicinal Properties
Aggarwal, B. B., BHATT, I. D., Ichikawa, H., Ahn, K. S., Sethi, G., Sandur, S. K., Sundaram, C., Seeram, N. P., & Shishodia, S. (2006) · Cited by 210
Morrow, P. K., Wulf, G. M., Ensor, J., Booser, D. J., Moore, J. A., Flores, P. R., Xiong, Y., Zhang, S., Krop, I. E., Winer, E. P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2321 · Cited by 209
“HER2 overexpression or gene amplification, which occurs in approximately 25% of all breast cancers, is associated with decreased disease-free survival and overall survival (OS).(1) Trastuzumab binds with high affinity to the extracellular domain of the HER2 receptor.”
BackgroundTranslating Pharmacogenomics: Challenges on the Road to the Clinic
Swen, J. J., Huizinga, T. W., Gelderblom, H., de Vries, E. G. E., Assendelft, W. J. J., Kirchheiner, J., & Guchelaar, H.-J. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040209 · Cited by 209
Somatic genetic changes in human breast cancer
Devilee, P. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90009-4 · Cited by 209
Price‐Schiavi, S. A., Jepson, S., Li, P., Arango, M., Rudland, P. S., Yee, L., & Carraway, K. L. (2002) · International Journal of Cancer · doi:10.1002/ijc.10410 · Cited by 209
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium
Pillai, R. N., Behera, M., Berry, L. D., Rossi, M. R., Kris, M. G., Johnson, B. E., Bunn, P. A., Ramalingam, S. S., & Khuri, F. R. (2017) · Cancer · doi:10.1002/cncr.30869 · Cited by 209
“0011) in patients with lymph node-positive breast cancer.(5) In patients with lymph node- negative disease, overexpression of the HER2 protein also portends worse outcomes as an independent prognostic factor for decreased 10-year recurrence-free survival (odds ratio, 1.”
BackgroundJensen, B. V., Johansen, J. S., & Price, P. A. (2003) · PubMed · Cited by 209
An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma
Barnes, D. M., Lammie, G. A., Millis, R. R., Gullick, W., Allen, D., & Altman, D. G. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.238 · Cited by 209
Kaptain, S., Tan, L. K., & Chen, B. (2001) · Diagnostic Molecular Pathology · doi:10.1097/00019606-200109000-00001 · Cited by 208
Lu, Y., Zi, X., & Pollak, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.11445 · Cited by 208
Adams, G., Schier, R., McCall, A., Crawford, R., Wolf, E., Weiner, L., & Marks, J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.233 · Cited by 208
Hortobagyi, G. N., Ueno, N. T., Xia, W., Zhang, S., Wolf, J. K., Putnam, J. B., Weiden, P. L., Willey, J. S., Carey, M., Branham, D. L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3422 · Cited by 208
Bièche, I., Olivi, M., Champème, M.-H., Vidaud, D., Lidereau, R., & Vidaud, M. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19981123)78:5<661::aid-ijc22>3.0.co;2-i · Cited by 208
Boyd, D. (1996) · Cancer and Metastasis Review · doi:10.1007/bf00049488 · Cited by 208
Prognostic Factors in Breast Cancer: Current and New Predictors of Metastasis
Hayes, D. F., Isaacs, C., & Stearns, V. (2001) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1014778713034 · Cited by 207
“Amplification of the gene and/or overexpression of the protein occurs in approximately 30% of breast cancers (60).”
BackgroundOncogene amplification in solid tumors
Schwab, M. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1999.0126 · Cited by 207
A tyrosine kinase profile of prostate carcinoma.
Robinson, D., He, F., Pretlow, T., & Kung, H. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5958 · Cited by 207
Thompson, J. E., & Thompson, C. B. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.103 · Cited by 206
ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a γ-secretase inhibitor
Osipo, C., Patel, P., Rizzo, P., Clementz, A. G., Hao, L., Golde, T. E., & Miele, L. (2008) · Oncogene · doi:10.1038/onc.2008.149 · Cited by 206
Overexpression of HER-2/neu in uterine serous papillary cancer.
Santin, A. D., Bellone, S., Gökden, M., Palmieri, M., Dunn, D. C., Agha, J., Roman, J. J., Hutchins, L. F., Pecorelli, S. L., O’Brien, T., et al. (2002) · PubMed · Cited by 206
Stefanick, J. F., Ashley, J. D., Kiziltepe, T., & Bilgicer, B. (2013) · ACS Nano · doi:10.1021/nn305663e · Cited by 205
“HER2 is overexpressed in 25% of breast cancer cases and is associated with poor prognosis making it an ideal receptor to target this disease.(42,43) In our approach, we used a short cyclicpeptide antagonist of HER2 as the targeting ligand and identified the optimal design elements for maximum cellular uptake.”
MethodHER2 Testing in Breast Cancer: NCCN Task Force Report and Recommendations
Carlson, R. W., Moench, S. J., Hammond, M. E. H., Perez, E. A., Burstein, H. J., Allred, D. C., Vogel, C. L., Goldstein, L. J., Somlo, G., Gradishar, W. J., et al. (2006) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2006.2003 · Cited by 205
Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer
Sonkar, K., Ayyappan, V., Tressler, C. M., Adelaja, O., Cai, R., Cheng, M., & Glunde, K. (2019) · NMR in Biomedicine · doi:10.1002/nbm.4112 · Cited by 205
Arteaga, C. L., Johnson, M. D., Todderud, G., Coffey, R. J., Carpenter, G., & Page, D. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10435 · Cited by 205
Going Digital: A Survey on Digitalization and Large-Scale Data Analytics in Healthcare
Tresp, V., Marc Overhage, J., Bundschus, M., Rabizadeh, S., Fasching, P. A., & Yu, S. (2016) · Proceedings of the IEEE · doi:10.1109/jproc.2016.2615052 · Cited by 149
“Also the characterization of the tumor is driven by molecular markers such as estrogen receptor, progesterone receptor and a genetic alteration, the HER2 amplification [113].”
BackgroundDillman, R. O. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0902 · Cited by 205
“It was soon appreciated that *25% of breast-cancer patients had tumors that overexpressed Her2 and that this was associated with a worse prognosis.(806) Anti-Her2 mAbs competitively inhibit the ability of the receptor to dimerize 22 DILLMAN”
BackgroundMitra, D., Brumlik, M. J., Okamgba, S. U., Zhu, Y., Duplessis, T. T., Parvani, J. G., Lesko, S. M., Brogi, E., & Jones, F. E. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0295 · Cited by 204
“HER2, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is overexpressed in 20% to 40% of invasive breast cancers and is associated with poor prognosis in these patients (8).”
BackgroundHeinmöller, P., Groß, C., Beyser, K., Schmidtgen, C., Maass, G., Pedrocchi, M., & Rüschoff, J. (2003) · PubMed · Cited by 204
Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.
McCann, A. H., Dervan, P. A., O'Regan, M. E., Codd, M., Gullick, W. J., Tobin, B. M., & Carney, D. N. (1991) · PubMed · Cited by 204
A novel doxycycline‐inducible system for the transgenic analysis of mammary gland biology
Gunther, E. J., Belka, G. K., Wertheim, G. B. W., Wang, J., Hartman, J. L., Boxer, R. B., & Chodosh, L. A. (2002) · The FASEB Journal · doi:10.1096/fj.01-0551com · Cited by 203
Guy, C. T., Muthuswamy, S. K., Cardiff, R. D., Soriano, P., & Muller, W. J. (1994) · Genes & Development · doi:10.1101/gad.8.1.23 · Cited by 203
Stancovski, I., Hurwitz, E., Leitner, O., Ullrich, A., Yarden, Y., & Sela, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8691 · Cited by 203
Self-citationBurstein, H. J., Storniolo, A. M., Franco, S., Forster, J., Stein, S., Rubin, S., Salazar, V. M., & Blackwell, K. L. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm601 · Cited by 203
“Between 20% and 25% of human breast cancers overexpress HER2 [4, 5]; HER2-positive breast cancer tends to be more aggressive and associated with a greater risk for disease recurrence and death [5, 6].”
BackgroundDynamic expression and activation of ERBB receptors in the developing mouse mammary gland.
Schroeder, J. A., & Lee, D. C. (1998) · PubMed · Cited by 202
Pestrin, M., Bessi, S., Galardi, F., Truglia, M., Biggeri, A., Biagioni, C., Cappadona, S., Biganzoli, L., Giannini, A., & Di Leo, A. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0461-7 · Cited by 201
“In the present study, we have used an immunomagneticbased, semiautomated technology namely CellSearch .I n a clinical setting, CTCs counting by CellSearch has been shown to have a prognostic value for advanced breast cancer patients [9, 10 ].”
BackgroundMethodErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma
Onda, M., Matsuda, S., Higaki, S., Iijima, T., Fukushima, J.-I., Yokokura, A., Kojima, T., Horiuchi, H., Kurokawa, T., & Yamamoto, T. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960101)77:1<71::aid-cncr13>3.0.co;2-5 · Cited by 201
De Keulenaer, G. W., Doggen, K., & Lemmens, K. (2010) · Circulation Research · doi:10.1161/circresaha.109.205906 · Cited by 201
Sørenmo, K. U., Worley, D. R., & Goldschmidt, M. H. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2362-5.00027-x · Cited by 203
Lu, C.-H., Wyszomierski, S. L., Tseng, L.-M., Sun, M.-H., Lan, K.-H., Neal, C. L., Mills, G. B., Hortobagyi, G. N., Esteva, F. J., & Yu, D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2837 · Cited by 200
“Breast cancer patients whose tumors overexpress the ErbB2 receptor tyrosine kinase have poor overall survival and shorter time to relapse (1).”
BackgroundGoldschmidt, M. H., Peña, L., & Zappulli, V. (2016) · Wiley eBooks · doi:10.1002/9781119181200.ch17 · Cited by 202
An update on the pathological classification of breast cancer
Rakha, E. A., Tse, G. M., & Quinn, C. M. (2023) · Histopathology · doi:10.1111/his.14786 · Cited by 199
“%) of these tumours are ERnegative.56,57 Numerous studies have shown that HER2 gene amplification/protein overexpression is a predictor of poor prognosis and response to certain types of chemotherapy.58-60 ER and HER2 are assessed in daily practice to provide information on response to endocrine therapy and anti-HER2…”
BackgroundTamoxifen: Catalyst for the change to targeted therapy
Jordan, V. C. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.11.002 · Cited by 199
“!) success of agents like trastuzumab that targets gene amplified HER2-neu (5) in select breast cancers to produce disease control (6–8) not previously thought possible.”
BackgroundCancer biomarker discovery and translation: proteomics and beyond
Hristova, V. A., & Chan, D. W. (2019) · Expert Review of Proteomics · doi:10.1080/14789450.2019.1559062 · Cited by 199
“For example, genetic alterations and increased expression of the human epidermal growth factor receptor 2 (HER2) tyrosine kinase are implicated in certain breast and ovarian cancers [33,34].”
BackgroundPark, B.-W., Zhang, H.-T., Wu, C., Berezov, A., Zhang, X., Dua, R., Wang, Q., Kao, G., O'Rourke, D. M., Greene, M. I., et al. (2000) · Nature Biotechnology · doi:10.1038/72651 · Cited by 199
“The use of full-length monoclonal antibodies in clinical applications may be limited by: (1) the difficulty or expense of commercialscale production (2) exclusion of monoclonal antibody from compartments such as the blood/brain barrier (3) limited ability for monoclonal antibodies to penetrate cells and tissues11, and…”
BackgroundPrediction of relapse and survival in breast cancer patients by pS2 protein status.
Ja, F., Rio, M., Seguin, P., Wl, V. P., Fauque, J., Nap, M., Jg, K., & Chambon, P. (1990) · PubMed · Cited by 199
Mechanisms of Therapeutic Antitumor Monoclonal Antibodies
Tsao, L.-C., Force, J., & Hartman, Z. C. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1109 · Cited by 198
Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer
de Melo Gagliato, D., Leonardo Fontes Jardim, D., Marchesi, M. S. P., & Hortobagyi, G. N. (2016) · Oncotarget · doi:10.18632/oncotarget.7043 · Cited by 198
“negative BC (TNBC) [3].”
Poon, K. A., Flagella, K., Beyer, J., Tibbitts, J., Kaur, S., Saad, O., Yi, J.-H., Girish, S., Dybdal, N., & Reynolds, T. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.09.003 · Cited by 198
MiR-124 targets Slug to regulate epithelial–mesenchymal transition and metastasis of breast cancer
Liang, Y.-J., Wang, Q.-Y., Zhou, C.-X., Yin, Q.-Q., He, M., Yu, X.-T., Cao, D.-X., Chen, G.-Q., He, J.-R., & Zhao, Q. (2013) · Carcinogenesis · doi:10.1093/carcin/bgs383 · Cited by 198
“It is derived from the sequential alteration of numerous oncogenes and tumor suppressors, such as HER2 (2), c-myc (3), BRCA1 (4) and so on.”
BackgroundFrequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus
Reichelt, U., Duesedau, P., Tsourlakis, M., Quaas, A., Link, B. C., Schurr, P. G., Kaifi, J. T., Gros, S. J., Yekebas, E. F., Marx, A. H., et al. (2006) · Modern Pathology · doi:10.1038/modpathol.3800712 · Cited by 198
“4 and is linked to poor prognosis within these tumors”
BackgroundUtilization of polymerase chain reaction technology in the detection of solid tumors
Raj, G. V., Moreno, J. G., & Gomella, L. G. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980415)82:8<1419::aid-cncr1>3.0.co;2-4 · Cited by 198
New clinical trial design in precision medicine: discovery, development and direction
Duan, X.-P., Qin, B.-D., Jiao, X.-D., Liu, K., Wang, Z., & Zang, Y.-S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 197
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
Kruschinski, A., Moosmann, A., Poschke, I., Norell, H., Chmielewski, M., Seliger, B., Kiessling, R., Blankenstein, T., Abken, H., & Charo, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804788105 · Cited by 197
Expression of the c‐erb B‐2 protein in normal and transformed cells
Gullick, W. J., Berger, M. S., Bennett, P. L. P., Rothbard, J. B., & Waterfield, M. D. (1987) · International Journal of Cancer · doi:10.1002/ijc.2910400221 · Cited by 197
Kiewe, P., Hasmüller, S., Kahlert, S., Heinrigs, M., Rack, B., Marmé, A., Korfel, A., Jäger, M., Lindhofer, H., Sommer, H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2436 · Cited by 197
Ríos-Luci, C., García-Alonso, S., Díaz-Rodríguez, E., Nadal-Serrano, M., Arribas, J., Ocaña, A., & Pandiella, A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3127 · Cited by 197
Focused Ultrasound Delivers Targeted Immune Cells to Metastatic Brain Tumors
Alkins, R., Burgess, A., Ganguly, M., Francia, G., Kerbel, R., Wels, W. S., & Hynynen, K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2609 · Cited by 197
Birner, P., Oberhuber, G., Stani, J., Reithofer, C., Samonigg, H., Hausmaninger, H., Kubista, E., Kwasny, W., Kandioler-Eckersberger, D., Gnant, M., et al. (2001) · PubMed · Cited by 197
The development and clinical use of trastuzumab (Herceptin).
Harries, M., & Smith, I. (2002) · Endocrine-related cancer · doi:10.1677/erc.0.0090075 · Cited by 196
“Slamon and colleagues initially reported that the HER-2 receptor was overexpressed in 20–30% of human breast cancers (Slamon et al. 1987).”
BackgroundInfluentialAn Anti-oncogenic Role for Decorin
Santra, M., Eichstetter, I., & Iozzo, R. V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006821200 · Cited by 196
Ben-Levy, R., Paterson, H. F., Marshall, C. J., & Yarden, Y. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06632.x · Cited by 196
De-regulated FGF receptors as therapeutic targets in cancer
Knights, V., & Cook, S. J. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.10.001 · Cited by 196
“HER2 is amplified and/or over expressed in about 30% of cases (Slamon et al., 1987), and antagonism of this receptor has prolonged disease-free survival; however, the molecular mechanism for tumour progression in the remaining 70% is poorly understood.”
BackgroundHorisawa, N., Adachi, Y., Takatsuka, D., Nozawa, K., Endo, Y., Ozaki, Y., Sugino, K., Kataoka, A., Kotani, H., Yoshimura, A., et al. (2022) · Breast Cancer · doi:10.1007/s12282-021-01303-3 · Cited by 196
Takegawa, N., Nonagase, Y., Yonesaka, K., Sakai, K., Maenishi, O., Ogitani, Y., Tamura, T., Nishio, K., Nakagawa, K., & Tsurutani, J. (2017) · International Journal of Cancer · doi:10.1002/ijc.30870 · Cited by 196
Carraway, K. L., Rossi, E. A., Komatsu, M., Price-Schiavi, S. A., Huang, D., Guy, P. M., Carvajal, M. E., Fregien, N., Carraway, C. A. C., & Carraway, K. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.9.5263 · Cited by 196
Initiating oncogenic event determines gene-expression patterns of human breast cancer models
Desai, K. V., Xiao, N., Wang, W., Gangi, L., Greene, J., Powell, J. I., Dickson, R., Furth, P., Hunter, K., Kucherlapati, R., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.102172399 · Cited by 196
Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance
Taneja, P., Maglic, D., Kai, F., Zhu, S., Kendig, R. D., Elizabeth, A., & Inoue, K. (2010) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s4773 · Cited by 196
Metadata
- Authors
- Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L.
- Affiliations
- University of California, Los Angeles (US)
- The University of Texas at San Antonio Health Science Center (US)
- Genentech (US)
- Venue
- Science
- Published
- 1987-01-09
- Volume
- 235
- Issue
- 4785
- Pages
- 177-182
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2141393790
- Cited by
- 11,760
- References
- 44
- Citations by year
- 2026: 209 · 2025: 230 · 2024: 301 · 2023: 309 · 2022: 302 · 2021: 346 · 2020: 336 · 2019: 325 · 2018: 344 · 2017: 395 · 2016: 416 · 2015: 433 · 2014: 486 · 2013: 549 · 2012: 459
- FWCI
- 103.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA36827, CA-30195)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- gene amplification, breast cancer, prognostic factors, relapse, overall survival, lymph node-positive disease, hormone receptor status, ErbB family, epidermal growth factor receptor
- MeSH terms
- Axilla, Breast Neoplasms, DNA, Female, Gene Amplification, Humans, Lymph Nodes, Neoplasm Recurrence, Local, Nucleic Acid Hybridization, Oncogenes, Prognosis, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.